Evidence map›Paper›PMID 20661409›Full record

ArticleInternational journal of clinical and experimental pathology2010

Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.

Vladislav Zakharov, Hsueh-Kung Lin, Joseph Azzarello, Scott McMeekin, Kathleen N Moore, Trevor M Penning, Kar-Ming Fung

Abstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Androgens in endometrial carcinoma: the killer or helper?Journal of endocrinological investigation · 2023
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Vladislav ZakharovDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. karmingfung@ouhsc.edu
Hsueh-Kung Lin
Joseph Azzarello
Scott McMeekin
Kathleen N Moore
Trevor M Penning
Kar-Ming Fung
University of Oklahoma Health Sciences Center · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
Human Aldo Keto Reductases and Steroid Hormone ActionR01CA090744 · NCI · UNIVERSITY OF PENNSYLVANIA · PI PENNING, TREVOR M · 2001 to 2011
$3.1M
NCI NIH HHS 1R01-CA90744NCI NIH HHS R01 CA090744NIEHS NIH HHS P30 ES013508NIEHS NIH HHS P30-ES013508
6 · The paper itself

Abstract

The diagnosis of endometrial hyperplasia and endometrial type adenocarcinoma arising within the uterine cavity has long been rested on morphologic criteria. Although distinction between normal endometrial epithelium from adenocarcinoma is usually straightforward, the separation between normal and hyperplastic endometrium, particularly those cases without atypia, can be a diagnostic challenge. The same is true in separation of hyperplastic endometrium with atypia from endometrial-type endometrial adenocarcinoma. Type 2 3alpha-/type 5 17beta-hydroxysteroid dehydrogenase (HSD) (AKR1C3) is a multifunctional enzyme involved in androgen, estrogen, progesterone, and pros-taglandin metabolism. Its expression has been shown in the epithelium of the renal tubules, urothelial epithelium, and endothelial cells in normal tissues as well as in prostatic adenocarcinoma. The proliferation and maintenance of endometrial epithelium is dependent on both estrogen and progesterone; and AKR1C3-mediated steroid metabolism may play a critical role in the maintenance of viable normal and abnormal endometrial epithelium. We studied the expression of AKR1C3 in 33 endometrial biopsy specimens including 13 cases of normal proliferative endometrium, 8 cases of hyperplastic endometrium with and without atypia, and 12 cases of primary endometrial adenocarcinoma of endometrial type. We demonstrated a uniform, diffuse, and strong expression of AKR1C3 in normal endometrial epithelium but not in endometrial stromal cells. In contrast, the expression of AKR1C3 is reduced in both hyperplastic and carcinomatous endometrial epithelium. These findings suggest that AKR1C3 may play important roles in the physiology of endometrial cells and that suppressed AKR1C3 expression may represent a feature that allows differentiation of hyperplastic and neoplastic endometrial epithelium from normal endometrial epithelium. However, reduced AKR1C3 expression cannot distinguish hyperplastic endometrium from endometrial adenocarcinoma of endometrial type. The biologic and pathological roles of AKR1C3 in endometrial epithelium require further investigation.

Indexed as

3-Hydroxysteroid DehydrogenasesAdenocarcinomaAldo-Keto Reductase Family 1 Member C3Biomarkers, TumorEndometrial HyperplasiaEndometrial NeoplasmsFemaleGene ExpressionGene Expression ProfilingHumansHydroxyprostaglandin DehydrogenasesImmunohistochemistry3-Hydroxysteroid DehydrogenasesAKR1C3 protein, humanAldo-Keto Reductase Family 1 Member C3Biomarkers, TumorHydroxyprostaglandin DehydrogenasesAldo-keto reductaseendomtrial cancerestrogenprogesteroneprostaglandin

Identifiers

PMID20661409
PMCPMC2907123
OpenAlexW1872057770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.